Steven Lichtman
Stock Analyst at Oppenheimer
(3.98)
# 436
Out of 4,814 analysts
65
Total ratings
43.48%
Success rate
13.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Maintains: Outperform | $115 → $105 | $68.61 | +53.04% | 8 | Oct 25, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $97.88 | +37.92% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $4.54 | +164.61% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $92.47 | +18.96% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $82.70 | +13.66% | 10 | Aug 21, 2024 | |
| RXST RxSight | Maintains: Outperform | $72 → $65 | $14.44 | +350.14% | 8 | Aug 6, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Outperform | $47 → $58 | $16.86 | +244.11% | 1 | Jun 10, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $10 → $11 | $8.32 | +32.21% | 5 | May 9, 2024 | |
| ANGO AngioDynamics | Upgrades: Outperform | $12 | $9.53 | +25.92% | 2 | Apr 5, 2024 | |
| MMSI Merit Medical Systems | Maintains: Outperform | $82 → $87 | $90.82 | -4.20% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $58 → $68 | $95.25 | -28.61% | 2 | Feb 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3.5 | $0.86 | +306.93% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $300 → $275 | $246.95 | +11.36% | 5 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $346.60 | -16.91% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $90.07 | +16.58% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $16.91 | +787.05% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $79.55 | +6.85% | 3 | Sep 4, 2020 |
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $68.61
Upside: +53.04%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $97.88
Upside: +37.92%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $4.54
Upside: +164.61%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $92.47
Upside: +18.96%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $82.70
Upside: +13.66%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $14.44
Upside: +350.14%
Tandem Diabetes Care
Jun 10, 2024
Maintains: Outperform
Price Target: $47 → $58
Current: $16.86
Upside: +244.11%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10 → $11
Current: $8.32
Upside: +32.21%
AngioDynamics
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $9.53
Upside: +25.92%
Merit Medical Systems
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $90.82
Upside: -4.20%
Feb 1, 2024
Maintains: Perform
Price Target: $58 → $68
Current: $95.25
Upside: -28.61%
Sep 19, 2023
Reiterates: Outperform
Price Target: $3.5
Current: $0.86
Upside: +306.93%
Jan 31, 2022
Upgrades: Outperform
Price Target: $300 → $275
Current: $246.95
Upside: +11.36%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $346.60
Upside: -16.91%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $90.07
Upside: +16.58%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $16.91
Upside: +787.05%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $79.55
Upside: +6.85%